Literature DB >> 17045219

Epidemiology of obesity and chronic kidney disease.

Will R Ross1, Janet B McGill.   

Abstract

The obesity epidemic has reached nephrology in the form of increasing numbers of patients with chronic kidney disease (CKD) caused by obesity-related metabolic disorders, IgA nephropathy, stone disease, and a unique glomerulopathy now known as obesity-related glomerulopathy (ORG). Obesity has been identified as an independent risk factor for CKD, and patients with central adiposity or high waist-to-hip ratios appear to have the highest risk. The metabolic syndrome is a risk factor for albuminuria and CKD, and studies now show that the risk of CKD increases with increased numbers of components of the metabolic syndrome. Obesity is not just a bystander or accelerator of other kidney diseases, but has unique histopathologic characteristics that can cause progressive kidney disease. ORG may accompany and worsen IgA nephropathy, urate nephropathy, and possibly even diabetic nephropathy. The origins of obesity-related kidney disease can be traced to insufficient glomerular complement from birth, and low birth weight may be an important precursor to obesity and its many comorbidities. Intervention strategies may need to target prenatal care through the elderly to combat this problematic epidemic.

Entities:  

Mesh:

Year:  2006        PMID: 17045219     DOI: 10.1053/j.ackd.2006.07.012

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  18 in total

Review 1.  Modulation of glomerulosclerosis.

Authors:  Li-Jun Ma; Agnes B Fogo
Journal:  Semin Immunopathol       Date:  2007-09-08       Impact factor: 9.623

2.  Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study.

Authors:  Ran Lee; Min-Ho Shin; Hee-Nam Kim; Young-Hoon Lee; Seong-Woo Choi; Hye-Ran Ahn; Sun-Seog Kweon
Journal:  Int Urol Nephrol       Date:  2017-07-21       Impact factor: 2.370

Review 3.  Kidney disease and obesity: epidemiology, mechanisms and treatment.

Authors:  Niels Olsen Saraiva Câmara; Kunitoshi Iseki; Holly Kramer; Zhi-Hong Liu; Kumar Sharma
Journal:  Nat Rev Nephrol       Date:  2017-01-16       Impact factor: 28.314

4.  The effect of obesity degree on childhood pulmonary function tests.

Authors:  Emel Torun; Erkan Cakir; Fatma Ozgüç; Ilker Tolga Ozgen
Journal:  Balkan Med J       Date:  2014-09-01       Impact factor: 2.021

5.  Epidemiology of urolithiasis: an update.

Authors:  Alberto Trinchieri
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

6.  Determination of early urinary renal injury markers in obese children.

Authors:  Nilufer Goknar; Faruk Oktem; Ilker Tolga Ozgen; Emel Torun; Mehmet Kuçukkoc; Aysegul Dogan Demir; Yasar Cesur
Journal:  Pediatr Nephrol       Date:  2014-05-07       Impact factor: 3.714

7.  Pathological influence of obesity on renal structural changes in chronic kidney disease.

Authors:  Shigeko Kato; Arifa Nazneen; Yumiko Nakashima; Mohammed S Razzaque; Tomoya Nishino; Akira Furusu; Noriaki Yorioka; Takashi Taguchi
Journal:  Clin Exp Nephrol       Date:  2009-04-29       Impact factor: 2.801

8.  Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities.

Authors:  A Gonzalez-Quintela; R Alende; F Gude; J Campos; J Rey; L M Meijide; C Fernandez-Merino; C Vidal
Journal:  Clin Exp Immunol       Date:  2007-11-15       Impact factor: 4.330

9.  Should prevention of chronic kidney disease start before pregnancy?

Authors:  Guido Filler; Meera S Rayar; Orlando da Silva; Ilan Buffo; Dion Pepelassis; Ajay P Sharma
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 10.  Progress and controversies: treating obesity and insulin resistance in the context of hypertension.

Authors:  Janet B McGill; Steven Haffner; Tomas J Rees; James R Sowers; Andrew M Tershakovec; Michael Weber
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-01       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.